January 2007
Mylan Laboratories Acquire Up to 71.5% Controlling Interest in Matrix Laboratories

January 2007
Matrix receives “Fastest Wealth Creator" in Motilal Oswal Wealth Creation Study for the year 2006. This is the third time in a row that Matrix has won the award, making it a hat-trick of outstanding achievement.

May 2006
Received “Best Management Award” from the Government of Andhra Pradesh

December 2005
Matrix receives "Fastest Wealth Creator" Award in the Motilal Oswal Wealth Creation Study consecutively for the year 2005.

December 2005
Matrix to acquire controlling stake in Concord Biotech, an Ahmedabad-based biotechnology company with fermentation & Bio-catalytic technology capabilities and US FDA approved API manufacturing facilities

November 2005
Matrix receives the National Award for R&D Efforts in Industry (2005) in Pharmaceuticals /Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology

June 2005
Matrix Laboratories Limited acquires controlling stake in Docpharma, Belgium.

April 2005
Matrix and Aspen, South Africa, to form two JVs.

February 2005
Matrix in strategic alliance with Mchem of China.

January 2005
Matrix receives "Fastest Wealth Creator" Award in the Motilal Oswal Wealth Creation Study, for the year 2004.

January 2005
Matrix Purchases Finished Dosage Facility Located near Nashik, about 150 km from Mumbai.

April 2004
Matrix signed definitive agreements with India Newbridge Investments Limited (an investment vehicle of the US-based Newbridge Capital) and Maxwell (Mauritius) Pte. Limited (an investment vehicle of the Singapore Government-owned Temasek Holdings) for the issue of 11,25,000 equity shares each to the two strategic investors at a price of Rs 1,500 per share on preferential basis.

March 2004
The Board of directors of Matrix approved the merger of Vera Laboratories Limited, Fine Drugs and Chemicals Limited, Medikon Laboratories Limited and Calibre Engineering Private Limited with itself. The proposed merger is subject to the approval of Shareholders, Honourable High Court of Andhra Pradesh and other regulatory bodies.

March 2004
Matrix has received USFDA approval for its manufacturing facility at Jeedimetla near Hyderabad. This would enable the company to roll out several active pharmaceutical ingredients (APIs) from its facility to the US markets.

November 2003
Matrix decided to set up two 50:50 joint venture companies, one in India and the other in Ireland, with a total capital outlay of 3.90 million Euros (Rs.21 crore). They would be set up in association with two German companies.

October 2003
Matrix has signed an agreement with William J Clinton Presidential Foundation for the supply of antiretroviral for the treatment of HIV and AIDS patients in Sub-Saharan Africa, South Africa and the Caribbean countries.

May 2003
Vorin Laboratories Limited and Medicorp Technologies India Limited have merged with Matrix Laboratories Limited.

April 2003
Matrix has successfully filed process Patent applications for 4 products at Indian Patent Office.

September 2002
In September 2002, Matrix Laboratories moved towards further consolidation by merging with Vorin Laboratories Limited an API Manufacturer with ISO 9000 certification.

May 2002
In May 2002, Matrix acquired 54.89% equity in Medicorp Technologies Limited, an API Manufacturer having US FDA approval, TGA Australia, ISO 9000, ISO 14000 certified. Has also been awarded the IDMA Quality Assurance Excellence Award consecutively for three years.

April 2002
On the 26th of April the API facility at Jeedimetla was approved by Therapeutic Goods Administration (TGA) by Regulatory Authority of Australia.

February 2002
Matrix filed process patent on Citalopram (API) on 27th February 2002.